Background: The available treatment options for Clostridium difficile infection (CDI) are limited by high recurrence rates. Surotomycin was a novel bactericidal cyclic lipopeptide in development to treat CDI that demonstrated non-inferiority to vancomycin in a Phase 2 trial.
Introduction
Clostridium difficile infection (CDI) remains a leading cause of hospital-acquired diarrhoea.
1,2 CDI incidence increased over the last decade, nearly doubling in the USA 1 in association with the high prevalence of epidemic NAP1/ribotype 027/BI strains. [3] [4] [5] Three antibiotics are routinely used for treatment: metronidazole, approved for anaerobic bacterial infections, though not specifically CDI; oral vancomycin; and fidaxomicin. 6, 7 In addition to the initial damage to the intestinal microbiome by antibiotics, causing CDI, vancomycin and metronidazole treatment further impairs the intestinal microbiome, a finding associated with recurrence rates of 16%-27% after treatment of primary episodes of CDI. 3, [8] [9] [10] Surotomycin (CB-183,315; MK-4261), a novel cyclic lipopeptide that disrupts the bacterial membrane of both logarithmic and stationary phase C. difficile, 11 was developed as an alternative treatment for CDI. Surotomycin has a narrow spectrum of activity, demonstrating low resistance rates and rapid activity against C. difficile, Enterococcus faecalis and Enterococcus faecium in vitro, with similar dose-and time-dependent pharmacodynamics to vancomycin in resolving CDI in a hamster model. 12, 13 Furthermore, surotomycin demonstrates greater in vitro activity against C. difficile than vancomycin or metronidazole 14 and is selective for C. difficile over Enterobacteriaceae and other Gram-negative anaerobes, such as Bacteroides fragilis. 15 The selectivity and lack of resistance associated with surotomycin suggested suitability for use of this treatment to reduce CDI recurrence. It was hypothesized that surotomycin may demonstrate non-inferiority to vancomycin for resolving CDI, and superiority in maintaining the clinical response and preventing recurrence in a larger cohort. Two parallel Phase 3 clinical trials were conducted to test these hypotheses: the first has been reported separately (MK-4261-005, ClinicalTrials.gov identifier: NCT01597505) 16 and the second is reported herein.
The primary objectives of this Phase 3 trial were to demonstrate the non-inferiority of surotomycin versus vancomycin in response rates at the end of treatment (EOT) and to evaluate the safety of surotomycin in adults with CDI. Key secondary objectives were to demonstrate clinical response over time and sustained clinical response superiority at trial completion of surotomycin over vancomycin, while comparing the efficacy of the two treatments.
Materials and methods

Ethics
The study was conducted in accordance with principles of Good Clinical Practice and was approved by the appropriate institutional review boards and regulatory agencies. The registration number of the study on ClinicalTrials.gov is NCT01598311. All participants provided written informed consent and the protocol was approved by the institutional review board at each participating institution.
Trial design
This trial was a randomized, double-blind, active-controlled investigation, consisting of two treatment arms (Protocol: MK-4261-006) conducted between July 2012 and August 2015. Enrolled patients underwent a 10 day treatment period (Days 1-10) and attended follow-up visits at 2 days after the EOT (Days 10-13), at Day 24 (+3 days) and between Days 40 and 50. The treatments administered were either oral twice-daily surotomycin 250 mg (alternated with twice-daily placebo) or four-times-daily vancomycin 125 mg. Clinical response at EOT and safety were the primary endpoints of the trial. Clinical response over time (time-to-event analysis) and sustained clinical response 30-40 days post-EOT (categorical analysis) were key secondary endpoints.
Trial population
Patients were enrolled at 104 sites, 70 in North America, 27 in Asia-Pacific and 7 in South America. Eligible patients were !18 and ,90 years old and presented diarrhoea with a minimum of three unformed bowel movements (UBMs), or .200 mL volume of stool for those using a collection device, over 24 h just prior to randomization and the first treatment dose. Patients testing positive for C. difficile toxin by enzyme immunoassay, PCR or cell culture cytotoxin neutralization assay within 48 h prior to the first treatment dose were included in the microbiological modified ITT (mMITT) population. Patients with toxic megacolon and/or small bowel ileus were excluded from the trial. Those who had a faecal transplant for the current episode of CDI, more than two episodes of CDI within 90 days, a history of inflammatory bowel disease, a positive stool culture for other enteropathogens, a life-threatening illness as identified by a score of 4 using a modified Horn's index 17 or a life-expectancy of ,8 weeks were also excluded.
Randomization and treatment
Eligible patients were randomly assigned (1:1) to the surotomycin or vancomycin treatments using a centralized computer-generated randomization schedule that was stratified by age (,75 or !75 years) and prior number of CDI episodes in the previous 90 days (0 or !1). Patients, trial staff and the sponsor remained blinded until database locking. Identification numbers and treatment kits were allocated via an interactive voice/web response system. To maintain the blind, patients in the surotomycin treatment arm received twice-daily placebo dummy treatments to match the four-timesdaily dosing regimen of vancomycin. Commercially available oral vancomycin tablets and the investigational surotomycin and placebo treatments were over-encapsulated and microcrystalline cellulose backfilled to prevent rattling. In both arms of the trial, a single capsule was administered at breakfast, lunch, dinner and bedtime during the 10 day treatment period.
Clinical outcomes
The clinical outcome was identified 2 days after EOT for each patient as clinical response [cure, i.e. clinical response, defined as resolution of diarrhoea ( 2 UBMs per 24 h period, or a 75% decrease in stool volume) for at least 2 consecutive days and no further antibiotic treatment required] or failure. Recurrence was identified between EOT and last follow-up visit when a patient demonstrated cure at EOT and subsequently experienced C. difficile toxin-positive diarrhoea, as defined by the inclusion criteria. If no recurrences occurred following cure at EOT until the final follow-up visit, sustained clinical response was achieved.
Microbiology
Baseline and recurrent diarrhoea samples were analysed on site for the detection of C. difficile toxin by ELISA, PCR, toxigenic culture or cell culture cytotoxin neutralization assay. Stool samples were also analysed for restriction endonuclease analysis type BI-and ribotype 027-positive epidemic strains of C. difficile at a central laboratory. Following recurrence or treatment failure, C. difficile isolates were assessed for relatedness to the baseline isolate and change in susceptibility to surotomycin or vancomycin (details are included in the Supplementary data available at JAC Online).
Pharmacokinetic (PK) evaluations
Blood samples were collected for this study and a selection of sites participated in an intensive PK sub-study, in which samples were collected on Days 5-7 at 0 (pre-dose) to 12 h post-dose after the patient had taken the first or third dose of the day. A spot stool sample was collected on Days 5-7 for analysis of study drug concentration for those patients participating in the intensive PK sampling. Parent surotomycin (plasma and faecal) and vancomycin (plasma) concentrations were determined by LC with tandem MS (LC-MS/MS; Tandem Laboratories, West Trenton, NJ, and Salt Lake City, UT, USA). The PK analysis population consisted of patients who provided at least three serial plasma samples post-dosing on Days 5-7 and a spot faecal sample in the same time period. Plasma PK parameters were determined by non-compartmental analysis in Phoenix WinNonlin V R (Pharsight Corporation, Mountain View, CA, USA).
Safety assessments
Non-serious adverse events (AEs) were documented from the time of first treatment dose until 7 days after the final dose. Serious AEs (SAEs) were documented from first treatment dose until 30 days after the final dose. Vital signs (heart rate, blood pressure and temperature), physical examination, electrocardiogram and laboratory safety tests were recorded throughout the trial.
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Data analysis and statistics
An 83% clinical response rate of CDI in the mMITT population for both surotomycin and vancomycin arms was assumed for determining the sample size. With this assumption, a sample size of 258 patients per arm would have !85% power to demonstrate surotomycin non-inferiority to vancomycin in clinical response rates at EOT, using a non-inferiority margin of 10% and at a one-sided significance level of 0.025. Assuming that 85% of randomized patients would be included in the mMITT population, $608 patients, 304 per arm, were required. The 10% non-inferiority margin was justified by using a 95%-95% fixed-margin approach. A treatment difference of active control versus placebo was estimated from the literature to be 29.6%. After discounting the estimated active-control effect by 30%, the non-inferiority margin of 10% still ensured preservation of 51.7% of the active-control effect. For the two predefined secondary superiority endpoints, the lower bound for a positive response or upper bound for a negative response of the two-sided 95% CI had to be .0% or ,0%, respectively.
The non-inferiority and superiority analyses of dichotomous endpoints used two-sided 95% CIs around the difference in clinical response rates at EOT in the mMITT population. The analyses were stratified by age (,75 or !75 years) and previous episodes of CDI in the last 90 days (0 or !1). Analyses were also performed stratified by the presence or absence of the epidemic BI/NAP1/027 strain at baseline.
The estimated proportion in each treatment group was calculated as a weighted average across all strata, constructed using Mehrotra Railkar continuity-corrected minimum-risk (MRc) stratum weights. 18 CIs were constructed using MRc weights with previously described methods. 19 The twosided 95% CIs for treatment group proportions were calculated as stratified Wilson CIs; two-sided 95% CIs for treatment difference were calculated as stratified Newcombe CIs. The Kaplan-Meier method was used to evaluate clinical response over time, with a stratified log-rank P value. Events were defined as treatment failure, CDI recurrence or death. All statistical tests were two-sided and conducted at the 0.05 significance level and descriptive statistics were provided for continuous data.
Results
Trial population
Six-hundred and eight patients were randomized to the trial: 303 to the surotomycin and 305 to the vancomycin treatment arm. Patient flow is shown in Figure 1 and the baseline demographic data of the mMITT population are shown in Table 1 
Efficacy
Two-hundred and thirty-seven patients (83.4%) in the surotomycin and 239 patients (82.1%) in the vancomycin treatment arm achieved clinical cure at EOT (Figure 2a ) and the non-inferiority endpoint was met (difference in percentage of patients 1.4%, 95% CI #4.9, 7.6). Neither of the two key secondary endpoints were met because surotomycin did not demonstrate superiority over vancomycin in sustained clinical response at the end of the trial (difference 4.3%, 95% CI #3.6, 12.2; Figure 2b ) or clinical response over time (stratified log-rank test P " 0.277; Figure 2c ).
In the surotomycin treatment arm, recurrence occurred in 57 patients (19.5%), while in the vancomycin treatment arm 66 patients experienced CDI recurrence (22.4%) and surotomycin superiority was not observed (difference #2.9%, 95% CI #9.5, 3.8). Time to resolution of diarrhoea following treatment was demonstrated by a Kaplan-Meier analysis to be similar between the treatments (stratified log-rank test P " 0.876). The median (95% CI) time to resolution of diarrhoea was 3.0 days (2.4, 4.0) for surotomycin and 3.3 days (2.5, 4.0) for vancomycin and therefore similar in both treatment arms.
Among the strains isolated from patients with treatment failure or CDI recurrence, there were two instances of surotomycin MIC increases upon surotomycin exposure for strains deemed or presumed related to the baseline isolate (full results are included in the Supplementary data).
In the baseline BI/NAP1/027-positive subpopulation, the rate of cure at EOT was numerically higher with vancomycin versus Daley et al. 
1).
In the baseline BI/NAP1/027-negative subpopulation, the rate of cure at EOT and sustained clinical response rate were numerically higher for surotomycin versus vancomycin, though the differences were not statistically significant (cure at EOT: surotomycin/vancomycin, 87.1%/81.7%; difference 5.4%, 95% CI #1.9, 12.6; Figure 3b ; sustained clinical response: 65.8%/62.2%; difference 3.6%, 95% CI #5.8%, 12.9%). Recurrence rates were similar for both treatments (surotomycin/vancomycin, 20.2%/18.5%; difference 1.7%, 95% CI #6.1, 9.5).
PK of surotomycin
Eighteen patients receiving surotomycin were included in the PK sub-study population. The median faecal concentration of surotomycin from the spot stool sample collected on Days 5-7 was 2028.9 lg/g (range 552-4960 lg/g). Plasma PK parameters of surotomycin and vancomycin are summarized in Table 2 .
Safety
Treatment-emergent AEs (TEAEs) were experienced by 154 (52.4%) surotomycin-treated patients and 181 (60.1%) vancomycin-treated patients (Tables 3 and 4 ). The incidence and types of AEs were generally typical of patients with a CDI diagnosis. The proportion of patients with at least one AE or SAE was numerically lower in the surotomycin group (Tables 3 and 4) ; the percentage of patients with AEs leading to discontinuation or death was also Daley et al.
similar in both treatment arms and none of the deaths was considered treatment related (Tables 3 and 4 ). Three patients in the surotomycin and three patients in the vancomycin treatment arm discontinued study medication due to treatment-related AEs.
The three surotomycin patients experienced severe headaches and severe abdominal cramps; severe elevated creatine phosphokinase (CPK); and moderate nausea, vomiting and dizziness, respectively. The three patients in the vancomycin treatment arm experienced moderate paraesthesias, moderate worsening of diarrhoea and severe abdominal cramps requiring narcotics and prolonged hospitalization, respectively. The highest frequency of AEs (system organ class) for both treatment arms was for gastrointestinal disorders followed by nervous system disorders, most commonly headaches ( Table 4) . The majority of TEAEs in both treatment arms (85.1% in the surotomycin and 87.3% in the vancomycin arm) were mild or moderate in intensity. The most common treatment-related TEAEs were nausea (4.1% in the surotomycin and 1.3% in the oral vancomycin arm) and headache (1.7% and 3.0%, respectively).
Four patients in the surotomycin and one in the vancomycin arm had CPK .1000 U/L post-baseline. One patient in the surotomycin and two in the vancomycin arm demonstrated ALT or AST .3 % upper limit of normal (ULN) and total bilirubin .2 % ULN; two patients in the surotomycin and five in the vancomycin arm Surotomycin primary outcomes of second Phase 3 trial JAC demonstrated ALT or AST .3 % ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash and/or eosinophilia. The three instances of ALT or AST .3 % ULN and total bilirubin .2 % ULN were within the range for potential Hy's law. None of these cases was deemed related to the trial drug.
Discussion
In a parallel Phase 3 study, surotomycin failed to demonstrate non-inferiority or superiority to vancomycin for the measured endpoints. 16 In the current trial, surotomycin demonstrated noninferiority to vancomycin for the treatment of adults with CDI at EOT. Thus, the primary endpoint of the trial was met. Neither of the two key secondary objectives (superiority of surotomycin over vancomycin for sustained clinical response, clinical response over time) was met. Therefore, surotomycin failed to demonstrate benefit over the existing vancomycin therapy. The lack of surotomycin superiority to vancomycin is consistent with the parallel Phase 3 trial. 16 However, the non-inferiority of surotomycin to vancomycin observed in the current trial is in contrast with the parallel trial.
Compared with the parallel Phase 3 trial, 16 the rate of clinical response at EOT for surotomycin was increased from 79.0% to 83.4% in the current trial. Meanwhile, vancomycin EOT cure rates were similar (82.1% in this trial and 83.6% in the parallel trial), and recurrence rates were slightly increased in the current trial for both surotomycin (19.5% versus 17.7% for this trial and the parallel trial, respectively) and vancomycin (22.4% versus 21.2%, respectively). In the current trial, sustained response rates were marginally higher for surotomycin (63.3%) versus the parallel trial (60.6%) and lower for vancomycin (59.0% versus 61.4% for this trial versus the parallel trial, respectively). The differences in response rates, recurrence rates and sustained clinical response rates between this trial and the parallel trial may be due to the baseline characteristics of enrolled patients.
Both of the surotomycin Phase 3 trials followed identical protocols; however, the demographics of the enrolled patients differed. In comparison with the parallel Phase 3 trial, the patients in the current trial were typically younger (mean age 57.1 versus 61.3 years), fewer were inpatients (45.4% versus 63.0%) and, more frequently, non-severe CDI was diagnosed (ESCMID comprehensive criteria for non-severe CDI, 32.6% in the current trial versus 25.6% in the parallel trial). The number of patients positive at baseline for BI/NAP1/027 was lower in the current compared with the parallel trial (16.2% versus 25.1%) and, furthermore, during the current trial a smaller proportion of patients used concomitant antibiotics (23.7% of patients) and proton pump inhibitors or histamine H 2 receptor antagonists (38.6% of patients) than in the parallel trial (26.8% of patients used antibiotics and 48.2% used proton pump inhibitors or H 2 receptor antagonists), all of which can increase CDI recurrence risk. 20 Although it is difficult to pinpoint one variable, differences in several of the variables listed above may have resulted in the slight differences seen in the results of the two pivotal Phase 3 trials.
Compared with the surotomycin Phase 2 trial, vancomycin recurrence rate was considerably lower (22.4% versus 35.6%) and sustained response rates were lower (70.1% versus 63.3% for 250 mg of surotomycin twice daily, and 70.1% versus 59.0% for vancomycin) in the current trial. 21 Rate of cure at EOT, sustained clinical response and recurrence for vancomycin were similar to those of both the parallel Phase 3 trial 16 and a previous Phase 3 trial analysing fidaxomicin. 22 BI/NAP1/027 incidence (16.2%) in the current trial was approximately half of that reported in previous studies, in which approximately one-third of individuals were shown to be positive for the strain at baseline, 21, 22 supporting a downward trend in the prevalence of the NAP1/ribotype 027/REA BI strain type. 23, 24 Similar to the parallel trial, surotomycin demonstrated reduced recurrence rates (surotomycin/vancomycin in parallel trial: 18.5%/32.0%) and increased sustained clinical response rates (surotomycin/vancomycin in parallel trial: 66.1%/51.5%) versus vancomycin in patients testing positive for BI/NAP1/027 at baseline. 16 When using the number of patients achieving cure as the denominator, the rates of recurrence in the current trial were 21% and 58% for surotomycin and vancomycin, respectively, in the BI/NAP1/027-positive population. Therefore, the initial cure rates alone cannot explain this difference.
The PK analysis from a small subset of the population demonstrated that plasma and faecal exposure to surotomycin varied greatly among patients. The faecal concentrations measured in the current trial exceeded the MIC of surotomycin against C. difficile (0.125-1 lg/mL) 11 in all patients. Despite achieving suitable faecal concentrations, $40% of patients ultimately failed CDI therapy in both this and the parallel Phase 3 trial. This rate is higher than in previous studies, 21, 22, 25 and the possible reason for this is likely to be the extended follow-up period, 30-40 days in this Patients were counted only once with the strongest relationship to trial drug. AEs with a missing relationship were analysed as related.
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Phase 3 trial compared with the 28 day follow-up used in earlier trials. Throughout this trial, as in previous trials, 16, 21 surotomycin was generally well tolerated in the patient population. There was a higher rate of CPK elevation associated with surotomycin versus vancomycin. Daptomycin, a compound related to surotomycin, also demonstrates this trend for elevated CPK values; however, musculoskeletal effects of this are reversible. 26 For efficacy data analyses presented in this manuscript, the mMITT population (including patients with protocol deviations) was used as the primary analysis population. Supportive analysis with per protocol populations that excluded patients with protocol deviations showed that the CDI recurrence rates were decreased in comparison with those seen in the mMITT population, but otherwise were in accord with and supported the findings of the mMITTbased analyses.
Given the findings of the Phase 3 clinical trials, the surotomycin development programme has been discontinued.
Conclusions
Twice-daily surotomycin at 250 mg met the primary efficacy endpoint of non-inferiority to four-times-daily vancomycin 125 mg for clinical response at EOT, but did not demonstrate superiority over four-times-daily vancomycin 125 mg for the key secondary endpoints of sustained clinical response and clinical response over time. Patients positive for BI/NAP1/027 at baseline experienced lower recurrence rates when treated with surotomycin versus vancomycin; however, this finding is nominal due to a lack of multiplicity control. Both surotomycin and vancomycin were generally well tolerated throughout the trial.
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